Tag: BÜHLMANN

Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease

BÜHLMANN IBDoc®: Orfanourdaki et al. The Real World Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease Under Maintenance Treatment with Adalimumab. UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain. P1074 Read Citation Health Canada Licence: 98903, Device class: 3 BÜHLMANN IBDoc® is Not Available for Sale in the US.

Clinical Trial Combines New Symptom App with IBDoc

Read a recent article from University of Otago on the success of a new smartphone app, IBDSmart, in synergy with BÜHLMANN IBDoc calprotectin home test. Highlight from this Article "The study showed there was no difference in terms of quality of life for patients whether they used the apps or had face-to-face meetings,” Associate Professor

BÜHLMANN Laboratories AG (BL), based in Basel Switzerland, has been discovering, developing & manufacturing innovative chemistry and immunological in-vitro diagnostic (IVD) and research use only (RUO) assays for almost 50 years (circa 1976). As the United States commercial affiliate of BL, BUHLMANN Diagnostics Corp (BDC), based in Amherst, NH is committed to providing exceptional sales, support, and technical services to our clinical, discovery and basic science research laboratory customers.

Tag: BÜHLMANN

Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease

Clinical Trial Combines New Symptom App with IBDoc

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US